DiaSorin offers a complete Borrelia line, on the LIAISON® systems.
The LIAISON® Borrelia IgM II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgM antibodies to Borrelia burgdorferi sensu lato in human serum, plasma or cerebrospinal fluid (CSF) samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Borrelia IgG assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to Borrelia burgdorferi sensu lato in human serum, plasma or cerebrospinal fluid (CSF) samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Borrelia IgM II assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to Borrelia burgdorferi sensu lato in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The diagnosis of Lyme borreliosis is based on clinical manifestations and history of exposure to ticks in an endemic area. Clinical manifestation of Lyme borreliosis may be similar to that of other diseases and serological detection of Borrelia antibodies represents a fundamental aid to diagnosis. Tests with high diagnostic accuracy are particularly important for differential diagnosis since additional factors complicate serological findings:
- early stage of infection may not show a measurable immune response
- IgM antibodies may persist for months
- cross-reaction with other spirochaete proteins, or other infectious diseases or autoimmune disorders may cause false positive antibody response